![Medicortex Finland Oyj](/data/images/00337/9222ebac-747b-4700-bb37-6f3300ae224f-w_300_h_100.jpg)
Medicortex Finland Plc appointing a new advisor
Medicortex is an innovative clinical stage biotechnology company focusing on development of diagnostics and therapy for brain injuries. Company’s short-term focus is to complete development of a rapid urine test, company’s lead product ProbTBITM kit for detection of biomarkers of mild traumatic brain injury, followed by prototype production and clinical evaluation. Professor Hannula will be part of the team to move the company forward to bring its breakthrough products to the clinics to address a significant unmet medical need.
Professor Hannula has a Doctor of Science degree from the Tampere University of Technology and his current position is Vice-Rector for partnerships and strategic engagement at the University of Turku, Finland. He has led the substantial extension of research and education at the University of Turku to technical sciences and headed the establishment of a new faculty of technology. Professor Hannula is an experienced leader and he has extensive experience in different academic leadership positions. Additionally, he serves as a board member or chair for several organizations inside and outside the academia, including private owned companies, public organizations and national defense.
“Medicortex is honored to have one of the most renowned and successful leaders in academia and strategic management to join the Medicortex team in this advisory position. We believe that we have assembled the top multidisciplinary advisory team", says Dr. Adrian Harel, CEO of Medicortex. “The broad potential of our TBI technology pipeline combined with the supplemented outstanding team of experts marks a major step forward in advancing Medicortex to the leading technology company in the field of noninvasive testing of head injury and beyond”, Dr. Harel adds.
“I am happy to join the Advisory Board of Medicortex”, Professor Hannula says. “I’m honored to be part of the team to advise the company at its extremely interesting stage to successfully move forward to get its products on the market. Brain injuries affect a large patient population and we have an outstanding opportunity to make major contributions towards finding an affordable test and reasonable treatment for patients with this condition”, Professor Hannula concludes.
Facts about Professor Mika Hannula
Name: Mika Hannula
Born: 1968
Current position: Vice-rector for partnerships and strategic engagement, University of Turku, Finland
Previous positions
- Director (part time), Technology Campus Turku
- President, Tampere University of Technology, Finland
- Professor at both University of Turku, and Tampere University of Technology
Other academic positions
- Chairman, advisory board of National Defense University, Finland
- Adjunct professor, National Defense University
- Adjunct professor, Tampere University
Education
- Doctor of Science (Tech), 1999
- Licentiate of Technology, 1998
- Master of Science (Tech) in Industrial Engineering and Management with distinction, 1993
Military rank: Lieutenant Colonel (in reserve)
Forward-looking statements
Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the results, operations, achievements and performance specifically or indirectly indicated in such forward-looking statements. Such risks, uncertainties and other important factors include, among other things, risks related to the implementation of the company’s strategy and availability of financing, general economic and market situation and other risks. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.
Keywords
Contacts
Adrian HarelCEO
Tel:+358 400 488 817adrian.harel@medicortex.fiLinks
About Medicortex Finland Oyj
Medicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an Israeli Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.
Subscribe to releases from Medicortex Finland Oyj
Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Medicortex Finland Oyj
Medicortex Finland Plc signed a 1.4 million dollars research grant contract with the U.S. Department of Defense24.6.2024 11:15:00 EEST | Press release
Medicortex Finland Plc, a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI), announces that the United States Department of Defense (“DoD”) has awarded the company a research grant of about 1.4 million dollars for its project plan to develop a rapid test for detection of mild traumatic brain injury (TBI) and concussion using saliva.
Medicortex Finland Plc appointing new members for the Board of Directors3.5.2024 09:51:16 EEST | Press release
Medicortex Finland Plc, a biotechnology company located in Turku, Finland, with a proprietary biomarker technology for detection of traumatic brain injury (TBI), announces appointment of Nils Grönberg and Ville Ranta-Panula (MSc, MBA) as new members in company’s Board of Directors. Grönberg and Ranta-Panula supplement the team of scientists and clinicians with their diverse expertise in business development and management, among other skills.
Medicortex Finland was granted a European patent related to the diagnostics of COVID-19 in saliva12.7.2023 09:07:35 EEST | Press release
Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics and drug for mild traumatic brain injury (TBI), was granted a European patent for COVID-19 diagnostics development. This patent protects Medicortex’s unique detection method of SARS-CoV-2 based on carbohydrates.
Turun kaupunki myönsi Medicortexille TKI-setelin15.6.2023 13:21:40 EEST | Tiedote
Medicortex Finland Oyj, turkulainen aivovammojen diagnostiikkaan ja lääkekehitykseen erikoistunut yritys, on saanut 5000 euron arvoisen TKI (tutkimus, kehitys- ja innovaatio-osaaminen) -setelin Turun kaupungilta. Seteli käytetään Turun yliopiston kanssa yhteistyössä tehtävän tutkimushankkeen edistämiseen. Hankkeen tarkoituksena on tutkia sähkömagneettisen säteilyn vaikutusta keskushermostoon koe-eläinmallissa.
Medicortexin kevään 2023 osakeanti päättynyt – yhtiö kiitollinen yleisön mielenkiinnosta30.5.2023 10:45:00 EEST | Tiedote
Medicortex Finland Oyj, tapaturmaisen aivovamman diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on saanut päätökseen osakeantikampanjan toisen kierroksen. Kampanjan aikana, joka sijoittui 2023 vuoden ensimmäiselle puolikkaalle, yritys keräsi yli 110 000 euroa. Saadut varat käytetään uusien hankkeiden aktivoimiseen yhtiön ensisijaisen tuotekehitysprojektin rinnalla.